Impact of Anti- T Lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results From a Prospective Randomized Double Blind Phase 3 Clinical Trial
Year: 2017
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Impact of Anti- T lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results from a Prospective Randomized Double Blind Phase 3 Clinical Trial.
Authors: Robert J. Soiffer, Haesook T. Kim, Yi-Bin Chen, Witold Rybka, Andrew S. Artz, Michael Boyer, Laura Johnston, Jim McGuirik, Thomas C. Shea, Paul J. Shaughnessy, Madan Jagasia, Carol Reynolds, Mahasweta Gooptu, Edwin P. Alyea, Vincent T. Ho, Frank Glavin, John F. DiPersio, Peter Westervelt, Jerome Ritz
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Massachusetts General Hospital, Pennsylvania State University, Penn State Cancer Institute, University of Chicago, University of Utah, Stanford Medicine, University of Kansas Medical Center, University of North Carolina at Chapel Hill, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Washington University in St. Louis
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2591164142